Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V: Chronic kidney disease and the global NCDs agenda. BMJ Glob Heal [Internet] 2: e000380, 2017 Available from: http://gh.bmj.com/lookup/doi/10.1136/bmjgh-2017-000380
Zhong J, Yang H-C, Fogo AB. A perspective on chronic kidney disease progression. Am J Physiol - Ren Physiol [Internet]. 2017;312:F375–84 Available from: http://ajprenal.physiology.org/lookup/doi/10.1152/ajprenal.00266.2016.
Article
CAS
Google Scholar
Richard J. Evolving importance of kidney disease : fro m subspecialty to global health burden. Lancet. [Internet] 382: 158–169, 2013 Available from: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60439-0/fulltext.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY-M, Yang C-W. Chronic kidney disease: global dimension and perspectives. Lancet (London, England) [Internet]. 2013;382:260–72 Available from: http://linkinghub.elsevier.com/retrieve/pii/S014067361360687X.
Article
Google Scholar
Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. Jama [Internet] 298: 2038. 2007; Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.298.17.2038.
Antlanger M, Bernhofer S, Kovarik JJ, Kopecky C, Kaltenecker CC, Domenig O, Poglitsch M, Säemann MD. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease. Ann Med [Internet]. 2017;49:525–33 Available from: https://www.tandfonline.com/doi/full/10.1080/07853890.2017.1313447.
Article
CAS
Google Scholar
Uzu T, Araki S, Kashiwagi A, Haneda M, Koya D, Yokoyama H, Kida Y, Ikebuchi M, Nakamura T, Nishimura M, Takahara N, Obata T, Omichi N, Sakamoto K, Shingu R, Taki H, Nagai Y, Tokuda H, Kitada M, Misawa M, Nishiyama A, Kobori H, Maegawa H. Comparative effects of direct renin inhibitor and angiotensin receptor blocker on albuminuria in hypertensive patients with type 2 diabetes. A randomized controlled trial. PLoS One [Internet]. 2016;11:e0164936 Available from: http://dx.plos.org/10.1371/journal.pone.0164936.
Article
Google Scholar
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM. Effect of finerenone on albuminuria in patients with diabetic nephropathy a randomized clinical trial. JAMA - J Am Med Assoc. 2015;314:884–94.
Article
CAS
Google Scholar
Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med [Internet] 358: 2433–2446, 2008 Available from: https://www.nejm.org/doi/full/10.1056/nejmoa0708379.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med [Internet] 345: 861–869, 2001 Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa011161
Kanno Y, Takenaka T, Nakamura T, Suzuki H. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol. 2006;1:730–7.
Article
CAS
Google Scholar
Iimori S, Naito S, Noda Y, Sato H, Nomura N, Sohara E, Okado T, Sasaki S, Uchida S, Rai T. Prognosis of chronic kidney disease with normal-range proteinuria: the CKD-ROUTE study. PLoS One. 2018;13:1–13.
Article
Google Scholar
Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.
Article
Google Scholar
Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med [Internet]. 2000;109:1–8 Available from: https://www.amjmed.com/article/S0002-9343(00)00444-7/fulltext.
Roscioni SS, Lambers Heerspink HJ, de Zeeuw D: Microalbuminuria: target for renoprotective therapy PRO. Kidney Int [Internet] 86: 40–49, 2014 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0085253815302519
Sforcin JM, Bankova V. Propolis: is there a potential for the development of new drugs? J Ethnopharmacol. 2011;133:253–60.
Article
CAS
Google Scholar
Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79:629–61.
Article
CAS
Google Scholar
Zaccaria V, Curti V, Di Lorenzo A, Baldi A, Maccario C, Sommatis S, Mocchi R, Daglia M. Effect of green and brown propolis extracts on the expression levels of microRNAs, mRNAs and proteins, related to oxidative stress and inflammation. Nutrients. 2017;9:1–17.
Article
Google Scholar
Berretta AA, Nascimento AP, Bueno PCP, de OL LVMM, Marchetti JM. Propolis standardized extract (EPP-AF ®), an innovative chemically and biologically reproducible pharmaceutical compound for treating wounds. Int J Biol Sci. 2012;8:512–21.
Article
Google Scholar
MacHado JL, Assunção AKM, Da Silva MCP, Reis AS Dos, Costa GC, Arruda DDS, Rocha BA, Vaz MMDOLL, Paes AMDA, Guerra RNM, Berretta AA, Nascimento FRF do: Brazilian green propolis: anti-inflammatory property by an immunomodulatory activity. Evidence-based Complement Altern Med 2012: 2012.
Orsatti CL, Missima F, Pagliarone AC, Bachiega TF, Búfalo MC, Araújo JP Jr, Sforcin JM. Propolis immunomodulatory action in vivo on toll-like receptors 2 and 4 expression and on pro-inflammatory cytokines production in mice. Phyther. Res. N/a-n/a; 2009.
Google Scholar
Patel S. Emerging adjuvant therapy for Cancer: Propolis and its constituents. J Diet Suppl. 2016;13:245–68.
Article
CAS
Google Scholar
Teles F, Da Silva TM, Da Cruz FP, Honorato VH, De Oliveira Costa H, Barbosa APF, De Oliveira SG, Porfírio Z, Libório AB, Borges RL, Fanelli C. Brazilian red propolis attenuates hypertension and renal damage in 5/6 renal ablation model. PLoS One. 2015;10:1–15.
Article
CAS
Google Scholar
Brätter C, Tregel M, Liebenthal C, Volk HD. Prophylactic effectiveness of propolis for immunostimulation: a clinical pilot study. Forsch Komplementarmed. 1999;6:256–60.
PubMed
Google Scholar
Samet N, Laurent C, Susarla SM, Samet-Rubinsteen N. The effect of bee propolis on recurrent aphthous stomatitis: a pilot study. Clin Oral Investig. 2007;11:143–7.
Article
Google Scholar
Yilmaz MI, Sonmez A, Saglam M, Kurt YG, Unal HU, Karaman M, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Vural A, Mallamaci F, Zoccali C. Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. Am J Nephrol. 2014;40:208–14.
Article
CAS
Google Scholar
Kang M-K, Park S-H, Kim Y-H, Lee E-J, Antika LD, Kim DY, Choi Y-J, Kang Y-H. Chrysin ameliorates podocyte injury and slit diaphragm protein loss via inhibition of the PERK-eIF2α-ATF-CHOP pathway in diabetic mice. Acta Pharmacol Sin. 2017;38:1129–40.
Article
CAS
Google Scholar
Kubota Y, Umegaki K, Kobayashi K, Tanaka N, Kagota S, Nakamura K, Kunitomo M, Shinozuka K. ANTI-HYPERTENSIVE EFFECTS OF BRAZILIAN PROPOLIS IN SPONTANEOUSLY HYPERTENSIVE RATS. Clin Exp Pharmacol Physiol. 2004;31:S29–30.
Article
Google Scholar
Mishima S, Yoshida C, Akino S, Sakamoto T. Antihypertensive effects of Brazilian propolis: identification of caffeoylquinic acids as constituents involved in the hypotension in spontaneously hypertensive rats. Biol Pharm Bull. 2005;28:1909–14.
Article
CAS
Google Scholar
Maruyama H, Sumitou Y, Sakamoto T, Araki Y, Hara H. Antihypertensive effects of flavonoids isolated from brazilian green propolis in spontaneously hypertensive rats. Biol Pharm Bull. 2009;32:1244–50.
Article
CAS
Google Scholar
Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, Cantley L, Devarajan P, Parikh CR, Coca SG. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: the ACCORD trial. Clin J Am Soc Nephrol. 2016;11:1343–52.
Article
Google Scholar
Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, Abe H, Iehara N, Fukatsu A, Okamoto H, Kita T, Doi T, Arai H. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun. 2007;360:772–7.
Article
CAS
Google Scholar
Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 2000;58:684–90.
Article
CAS
Google Scholar
Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activate. J Int Med Res. 2007;35:482–9.
Article
CAS
Google Scholar
Tumlin JA, Galphin CM, Rovin BH. Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1. J Diabetes Res. 2013;2013.
Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of Pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis. 2008;52:464–74.
Article
CAS
Google Scholar
Ble A, Mosca M, Di Loreto G, Guglielmotti A, Biondi G, Bombardieri S, Remuzzi G, Ruggenenti P. Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am J Nephrol. 2011;34:367–72.
Article
CAS
Google Scholar
Li YJ, Lin JL, Yang CW, Yu CC. Acute renal failure induced by a Brazilian variety of propolis. Am J Kidney Dis. 2005;46:125–9.
Article
Google Scholar
Naramoto K, Kato M, Ichihara K. Effects of an ethanol extract of brazilian green propolis on human cytochrome P450 enzyme activities in vitro. J Agric Food Chem. 2014;62:11296–302.
Article
CAS
Google Scholar